Vaccines and Methods of Treating Drug-Resistant HIV-1 and Hepatitis B Viruses


This technology relates to methods for lowering a viral load of a virus where the virus causes a chronic viral infection and is resistant to an antiviral drug. The method comprises administering to a host a medicament comprising an antiviral drug to restrict the intracellular multiplication of the virus and that is capable of selecting for a predetermined antiviral drug-resistant mutation in a viral protein. The medicament further comprises a synthetic peptide that comprises the predetermined antiviral drug-resistant mutation and at least six amino acid residues flanking that mutation that are identical to the amino acid sequence of the viral protein of the antiviral drug-resistant virus. The synthetic peptide induces a cytotoxic T lymphocyte (CTL) response specific for cells infected with the antiviral drug-resistant virus. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved. Further, the compositions and methods of this technology are useful to target many viruses that can develop antiviral drug resistance, including HIV-1, HIV-2, hepatitis B virus, hepatitis C virus, and human herpesviruses.



Potential Commercial Applications: Competitive Advantages:
  • Therapeutic treatment using an antiviral drug in combination with a synthetic peptide for patients with viral infections
  • Treatment to induce immune response in patients with drug resistance viral infections
 
  • Applicable to a wide variety of infectious diseases
  • Can be used in combination with antiviral drugs


Development Stage:
Pre-clinical (in vivo)

Inventors:

Andrew Catanzaro (NCI)  ➽ more inventions...

Jay Berzofsky ()  ➽ more inventions...


Intellectual Property:

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-137-2003
Updated: Dec 10, 2018